WAP
IMMU

Wealthcare Advisory Partners’s Immunomedics Inc IMMU Stock Holding History

Wealthcare Advisory Partners’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-5,813
Closed -$85K – 1351
2018
Q1 		$85K Buy
+5,813
New +$95K 0.02% 310

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Wealthcare Advisory Partners's IMMU Position: Q2 2018 in Review

Wealthcare Advisory Partners sold out of Immunomedics Inc (IMMU) in Q2 2018, closing a stake of 5,813 shares — an estimated $85K sold.

Wealthcare Advisory Partners first reported a position in IMMU in Q1 2018 and held it in 1 quarter. The position peaked at $85K in Q1 2018. 192 funds tracked by Wall St. Rank hold IMMU as of Q2 2018.

  • Wealthcare Advisory Partners reported no remaining Immunomedics Inc position as of Q2 2018 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 5,813 Immunomedics Inc shares in Q2 2018, an estimated $85K.
  • Wealthcare Advisory Partners first reported a position in Immunomedics Inc in Q1 2018 and held it in 1 quarter.
  • Wealthcare Advisory Partners's Immunomedics Inc position peaked at $85K in Q1 2018.
  • 192 funds tracked by Wall St. Rank held Immunomedics Inc as of Q2 2018.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2018, filed 14 Aug 2018.